These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 12794086)
41. Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells. Peng B; Fleming JB; Breslin T; Grau AM; Fojioka S; Abbruzzese JL; Evans DB; Ayers D; Wathen K; Wu T; Robertson KD; Chiao PJ Clin Cancer Res; 2002 Nov; 8(11):3628-38. PubMed ID: 12429655 [TBL] [Abstract][Full Text] [Related]
42. Expression of functional Schistosoma mansoni Smad4: role in Erk-mediated transforming growth factor beta (TGF-beta) down-regulation. Osman A; Niles EG; LoVerde PT J Biol Chem; 2004 Feb; 279(8):6474-86. PubMed ID: 14630909 [TBL] [Abstract][Full Text] [Related]
43. Heterogeneities in the biological and biochemical functions of Smad2 and Smad4 mutants naturally occurring in human lung cancers. Yanagisawa K; Uchida K; Nagatake M; Masuda A; Sugiyama M; Saito T; Yamaki K; Takahashi T; Osada H Oncogene; 2000 May; 19(19):2305-11. PubMed ID: 10822381 [TBL] [Abstract][Full Text] [Related]
44. The N domain of Smad7 is essential for specific inhibition of transforming growth factor-beta signaling. Hanyu A; Ishidou Y; Ebisawa T; Shimanuki T; Imamura T; Miyazono K J Cell Biol; 2001 Dec; 155(6):1017-27. PubMed ID: 11739411 [TBL] [Abstract][Full Text] [Related]
45. Regulation of large-scale chromatin unfolding by Smad4. Yan J; Fang Y; Ding L; Zhu J; Lu Q; Huang C; Yang X; Ye Q Biochem Biophys Res Commun; 2004 Mar; 315(2):330-5. PubMed ID: 14766211 [TBL] [Abstract][Full Text] [Related]
46. Ligand-dependent degradation of Smad3 by a ubiquitin ligase complex of ROC1 and associated proteins. Fukuchi M; Imamura T; Chiba T; Ebisawa T; Kawabata M; Tanaka K; Miyazono K Mol Biol Cell; 2001 May; 12(5):1431-43. PubMed ID: 11359933 [TBL] [Abstract][Full Text] [Related]
47. Transcriptional activating activity of Smad4: roles of SMAD hetero-oligomerization and enhancement by an associating transactivator. Shioda T; Lechleider RJ; Dunwoodie SL; Li H; Yahata T; de Caestecker MP; Fenner MH; Roberts AB; Isselbacher KJ Proc Natl Acad Sci U S A; 1998 Aug; 95(17):9785-90. PubMed ID: 9707553 [TBL] [Abstract][Full Text] [Related]
48. Transforming growth factor-beta receptor-associated protein 1 is a Smad4 chaperone. Wurthner JU; Frank DB; Felici A; Green HM; Cao Z; Schneider MD; McNally JG; Lechleider RJ; Roberts AB J Biol Chem; 2001 Jun; 276(22):19495-502. PubMed ID: 11278302 [TBL] [Abstract][Full Text] [Related]
49. Ubiquitination and proteolysis of cancer-derived Smad4 mutants by SCFSkp2. Liang M; Liang YY; Wrighton K; Ungermannova D; Wang XP; Brunicardi FC; Liu X; Feng XH; Lin X Mol Cell Biol; 2004 Sep; 24(17):7524-37. PubMed ID: 15314162 [TBL] [Abstract][Full Text] [Related]
50. Aberrant expression of Smad4 results in resistance against the growth-inhibitory effect of transforming growth factor-beta in the SiHa human cervical carcinoma cell line. Lee S; Cho YS; Shim C; Kim J; Choi J; Oh S; Kim J; Zhang W; Lee J Int J Cancer; 2001 Nov; 94(4):500-7. PubMed ID: 11745435 [TBL] [Abstract][Full Text] [Related]
51. Novel mutations in Smad proteins that inhibit signaling by the transforming growth factor beta in mammalian cells. Prokova V; Mavridou S; Papakosta P; Petratos K; Kardassis D Biochemistry; 2007 Dec; 46(48):13775-86. PubMed ID: 17994767 [TBL] [Abstract][Full Text] [Related]
52. Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis. Imai Y; Kurokawa M; Izutsu K; Hangaishi A; Maki K; Ogawa S; Chiba S; Mitani K; Hirai H Oncogene; 2001 Jan; 20(1):88-96. PubMed ID: 11244507 [TBL] [Abstract][Full Text] [Related]
53. TGF-beta-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines. Fink SP; Mikkola D; Willson JK; Markowitz S Oncogene; 2003 Mar; 22(9):1317-23. PubMed ID: 12618756 [TBL] [Abstract][Full Text] [Related]
54. A novel transcriptional factor with Ser/Thr kinase activity involved in the transforming growth factor (TGF)-beta signalling pathway. Ohta S; Takeuchi M; Deguchi M; Tsuji T; Gahara Y; Nagata K Biochem J; 2000 Sep; 350 Pt 2(Pt 2):395-404. PubMed ID: 10947953 [TBL] [Abstract][Full Text] [Related]
55. Xenopus Smad4beta is the co-Smad component of developmentally regulated transcription factor complexes responsible for induction of early mesodermal genes. Howell M; Itoh F; Pierreux CE; Valgeirsdottir S; Itoh S; ten Dijke P; Hill CS Dev Biol; 1999 Oct; 214(2):354-69. PubMed ID: 10525340 [TBL] [Abstract][Full Text] [Related]
56. Interaction of smad3 with a proximal smad-binding element of the human alpha2(I) procollagen gene promoter required for transcriptional activation by TGF-beta. Chen SJ; Yuan W; Lo S; Trojanowska M; Varga J J Cell Physiol; 2000 Jun; 183(3):381-92. PubMed ID: 10797313 [TBL] [Abstract][Full Text] [Related]
57. Critical role for lysine 133 in the nuclear ubiquitin-mediated degradation of MyoD. Batonnet S; Leibovitch MP; Tintignac L; Leibovitch SA J Biol Chem; 2004 Feb; 279(7):5413-20. PubMed ID: 14660660 [TBL] [Abstract][Full Text] [Related]
58. Contribution of the constitutive and inducible degradation of Smad3 by the ubiquitin-proteasome pathway to transforming growth factor-beta signaling. Inoue Y; Kitagawa M; Onozaki K; Hayashi H J Interferon Cytokine Res; 2004 Jan; 24(1):43-54. PubMed ID: 14980084 [TBL] [Abstract][Full Text] [Related]
59. The tumor suppressor Smad4/DPC 4 as a central mediator of Smad function. Zhang Y; Musci T; Derynck R Curr Biol; 1997 Apr; 7(4):270-6. PubMed ID: 9094310 [TBL] [Abstract][Full Text] [Related]
60. A structural basis for mutational inactivation of the tumour suppressor Smad4. Shi Y; Hata A; Lo RS; Massagué J; Pavletich NP Nature; 1997 Jul; 388(6637):87-93. PubMed ID: 9214508 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]